We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subc... Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. Show more
Ask ADVFN Intelligence (AI)
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 4.37 | 12.2856339612 | 35.57 | 41.87 | 35.13 | 1004592 | 38.04001248 | CS |
| 4 | 3.46 | 9.48464912281 | 36.48 | 41.87 | 29.1 | 763926 | 34.75011441 | CS |
| 12 | -6.54 | -14.0705679862 | 46.48 | 50.56 | 29.1 | 583111 | 38.1745391 | CS |
| 26 | -11.99 | -23.0887733487 | 51.93 | 63.5 | 29.1 | 521835 | 45.02951672 | CS |
| 52 | -29.77 | -42.7054941902 | 69.71 | 71.75 | 29.1 | 497747 | 48.00578939 | CS |
| 156 | 18.44 | 85.7674418605 | 21.5 | 72.29 | 14.19 | 461305 | 42.51103462 | CS |
| 260 | 18.44 | 85.7674418605 | 21.5 | 72.29 | 14.19 | 461305 | 42.51103462 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
